Skip to main content
. Author manuscript; available in PMC: 2024 Jan 1.
Published in final edited form as: Int Forum Allergy Rhinol. 2023 Mar 30;13(7):1061–1482. doi: 10.1002/alr.23079

TABLE VIII.A.5.h.

Evidence for treatment of TECSA

Study Year LOE Study design Study group Clinical end-point Conclusion
Morgenthaler et al.1052 2014 1b RCT 1) ASV; 2) CPAP Primary endpoint: AHI < 10 at 90 days;
Secondary endpoints: compliance, ESS, and SAQLI
1) ASV reduces AHI more than CPAP.
Dellweg et al.1049 2013 1c RCT 1) ASV; 2) NPPV (bilevel PAP with backup rate) Primary endpoint: AHI after 6 weeks.
Secondary endpoint: AHI on ASV titration
1) ASV showing sustained significant improvement at 6 weeks; 2) ASV and NPPV similarly treated TECSA on the titration.
Javaheri et al.1183 2011 1c RCT 1) ASV (BiPAP autoSV Advanced); 2) ASV (BiPAP autoSV) Primary endpoint: AHI on ASV titration 1) BiPAP autoSV Advanced lowered AHI more than BiPAP autoSV.
Pépin et al.1053 2018 3b Case–control 1) CPAP switched to ASV; 2) ASV; 3) CPAP Primary endpoint: Adherence data;
Secondary endpoint: Average AHI
1) Increased adherence in patients switching from CPAP to ASV.
2) Lower AHI in patients switching from CPAP to ASV.
Heider et al.1184 2018 3b Case–control 1) HFpEF with TECSA; 2) HFpEF with CSA Primary endpoint: Sleep fragmentation and quality at ASV titration and after 27 months of ASV use 1) AHI and arousal index improve with ASV.
2) Increased sleep efficiency only in TESCA group with ASV.
3) ESS improves with ASV.
Neu et al.1186 2017 3b Case–control 1) AutoCPAP with TECSA; 2) AutoCPAP without TECSA Primary endpoint: AHI;
Secondary endpoints: Quality of life, sleep fragmentation
1) Auto-titrating CPAP has relative treatment failure for TECSA compared to those without TECSA.
Kuzniar et al.1046 2011 3b Retrospective cohort 1) ASV (VPAP AdaptSV); 2) ASV (BiPAP autoSV) Primary endpoint: AHI;
Secondary endpoints: adherence data, sleepiness using ESS
1) Both ASV devices were comparable.
2) Baseline populations were
significantly different.
Allam et al.1047 2007
3bCase–control
1) ASV; 2) CPAP; 3) BPAP-S; 4) BPAP-ST; CPAP + O2 Primary endpoint: AHI on titration 1) ASV reduced AHI more than other modalities.
Javaheri et al.1185 2015 4 Case series 1) ASV using default settings Primary endpoint: AHI; Secondary endpoints: subjective sleep quality using Likert scale and adherence and therapy data at 90 days 1) Default ASV settings improve AHI.
2) Adherence, sleep disordered breathing, ESS, and subjective sleep quality are improved at 90 days.
Brown et al.1048 2011 4 Case series 1) ASV Primary endpoint: AHI on titration ASV can be effective in reducing AHI.